<DOC>
	<DOCNO>NCT01699633</DOCNO>
	<brief_summary>Nevirapine prefer nonnucleoside reverse transcriptase inhibitor ( NNRTI ) treatment HIV child young 3 year old tuberculosis ( TB ) coinfection . However , limited data drug-drug interaction rifampin nevirapine child age group . The purpose study determine effect rifampin-containing anti-TB treatment blood level nevirapine young child HIV TB coinfection . Also , study find whether check genetic makeup child could help determine appropriate dose nevirapine set concomitant anti-TB treatment .</brief_summary>
	<brief_title>Rifampin Nevirapine Interactions Young Children</brief_title>
	<detailed_description>HIV TB coinfection common major cause death child globally . Treatment two infection together time save life TB medication significant drug-drug interaction commonly use antiretroviral drug ( ARVs ) . Rifampin induce activity cytochorme P450 ( CYP ) enzymes may reduce blood level important ARVs nevirapine efavirenz coadministered . The CYP enzymes activity vary person person depend genetic makeup , complicate drug-drug interaction . Nevirapine undergoes extensive metabolism hepatic CYP3A CYP2B6 enzymes . The induction CYP3A4 2B6 rifampin cause 10 - 68 % reduction nevirapine exposure upon concomitant dosing adult . Pharmacokinetic study suggest nevirapine trough concentration HIV-infected child tend low sub-therapeutic child young 3 year old . To knowledge , study evaluate influence rifampin nevirapine plasma concentration young child report substantial reduction nevirapine concentration rifampin co-administration . It currently unclear whether use recommended nevirapine dose ( 200 mg/m2 twice daily ) without two-week lead-in 200 mg/m2 daily overcome risk sub-therapeutic concentration set concomitant anti-TB treatment . This study investigate effect rifampin-containing anti-TB therapy nevirapine plasma concentration child young 3 year old , well find whether CYP2B6 CYP3A4 enzymes genetic polymorphism influence magnitude drug-drug interaction . Specific hypothesis test : 1 . Rifampin-containing anti-TB therapy substantially reduce nevirapine Cmin estimate AUC0-12h young HIV-infected child ( least 40 % ) . 2 . CYP2B6 extensive metabolizers substantially low plasma nevirapine Cmin estimate AUC0-12h presence absence rifampin-containing TB therapy , significant difference intermediate slow metabolizers . A two-arm parallel assignment pharmacokinetic study TB/HIV co-infected child perform KATH . Children age 3 - 35 month HIV infection without TB coinfection , antiretroviral therapy ( ART ) -naïve , previously expose nevirapine enrol . The ART regimen consist nevirapine 200 mg/m2 plus zidovudine ( ZDV ) 180 - 240 mg/m2 lamivudine ( 3TC ) 4 mg/kg twice daily accordance WHO guideline . There lead-in dosing nevirapine co-infected patient rifampin . The dose nevirapine HIV mono-infected group 200 mg/m2 daily x 2 week twice daily afterwards . Standard anti-TB therapy prescribe HIV/TB co-infected patient . Anti-TB treatment start immediately upon diagnosis . Antiretroviral therapy start soon anti-TB therapy tolerate ( typically within 2 8 week ) . A complete medical history , physical examination , stag HIV disease perform initiation ART subsequent study visit . Relevant data collect use standardized form . Baseline measurement prior initiation ART include complete blood count ( CBC ) , blood urea nitrogen , creatinine , liver function test ( LFTs ) , CD4 cell count determination plasma HIV-1 RNA level . Measurements CD4 cell count plasma HIV-1 RNA repeat week 12 24 start ART . All study participant follow-up 2 4 week , well monthly assessment treatment side effect . Additional test do clinically indicated evaluate drug toxicity . Pharmacokinetic testing perform week 4 ART arm 4 week anti-TB treatment stop child receive ART HIV/TB co-infected group . All patient admit hospital night prior complete PK sampling . Study drug administer least 2-hour fast non-breastfed child . Younger child exclusive breast-feeding allow breast feed need throughout study . At sample time , 2 mL blood collect EDTA tube time 0 , 2 , 6 12 hour post-dose determination nevirapine concentration . Actual time sample record . The blood sample centrifuge 3000g 10 minute plasma store - 70oC measurement plasma drug concentration . Nevirapine concentration plasma measure use validate gas chromatography mass spectrometry nonlinear mixed-effects modeling ( use NONMEM , version VI ) use estimate pharmacokinetic parameter ( CL/F , AUC , Cmin , Cmax ) , inter-individual error , residual error . DNA sample store genotyping drug metabolize enzyme transporter .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>1 . HIV seropositive child without active TB 2 . Aged 3 35 month old 3 . Antiretroviralnaïve meet criterion initiation antiretroviral therapy 4 . Are available followup achievement study endpoint like completion study discontinuation HAART , and/or PK sample 1 . Unable obtain informed sign consent parent ( ) legal guardian 2 . Have AIDSrelated opportunistic infection TB , history proven acute hepatitis within 30 day study entry , persistent vomiting , diarrhea 3 . Hemoglobin &lt; 6 g/dl , white blood cell &lt; 2500/mm3 , serum creatinine &gt; 1.5 mg/dl , AST ALT &gt; 2X upper limit normal .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Drug-gene interaction</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Rifampicin</keyword>
	<keyword>child</keyword>
</DOC>